CATX 250117 5.00P (CATX250117P5000) Stock Options, News & Quotes

US OptionsDetailed Quotes

CATX250117P5000

Watchlist

1.86
-1.29-40.95%

15min DelayClose Jan 17 16:00 ET

1.86High1.86Low

Intraday

5D
Daily

News

RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $16
Moomoo NewsJan 15 21:31 ET · Ratings
JonesTrading Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
Moomoo NewsJan 15 09:31 ET · Ratings
Perspective Therapeutics' Strategic Advancements and Positive Clinical Developments Justify Buy Rating
TipRanksJan 15 09:25 ET · Ratings
RBC Capital Reiterates Outperform on Perspective Therapeutics, Maintains $16 Price Target
BenzingaJan 14 11:44 ET · Ratings
Perspective Therapeutics Analyst Ratings
BenzingaJan 14 11:41 ET · Ratings
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating
Moomoo NewsJan 14 07:36 ET · Ratings

Comments

Jaguar8

Nov 22, 2024 13:52

Easy 16% 😉

$Perspective Therapeutics (CATX.US)$

Johnny Mnemonic

Nov 22, 2024 10:12

I don't trust nobody
I don't even trust my mind
losing everybody
they can never take my grind

Jaguar8

Nov 21, 2024 23:09

On watchlist. Reason: Presentation today. Possible PR tomorrow

$Perspective Therapeutics (CATX.US)$

Stock_Drift

Nov 15, 2024 16:17

After Hours Ticks. 5:16pm 11/15🦌

$Scorpius Holdings (SCPX.US)$ $Perspective Therapeutics (CATX.US)$ $Turbo Energy (TURB.US)$ $Adverum Biotechnologies (ADVM.US)$ $NFT Ltd (MI.US)$ $Xylo Technologies (XYLO.US)$ $Lipocine (LPCN.US)$ $Massimo (MAMO.US)$ $China Jo-Jo Drugstores (CJJD.US)$ $Edesa Biotech (EDSA.US)$ $Atara Biotherapeutics (ATRA.US)$ $Eterna Therapeutics (ERNA.US)$ $DDC Enterprise (DDC.US)$
📊⚡️📊

Trytosaveabit

Nov 15, 2024 15:13

Watching! Note the dates!

$Perspective Therapeutics (CATX.US)$ Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today released details regarding the upcoming presentation of initial results from the Company-sponsored Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium t...